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1 Introduction
In 1991, Mark Weiser predicted that the technology that most inﬂuences us is the technology that disappears
before our eyes and weaves itself completely into our everyday lives (Weiser 1991). Almost a quarter of a
century later, we already rely on such developments on a daily basis: smartphones, tablets, smart watches
and data glasses; what is on offer is growing with the miniaturisation of technology. Basically, these devices
are high-performance computers “en miniature” and they are either incorporated into, or even created as,
everyday objects. The market is not only growing for these devices, but also for the software with which
they operate. Increasingly, platforms are being created whereby third parties can provide their own computer
programs which are commonly referred to as “apps”.
Mobile devices and apps are also ﬁnding their way into the health sector. “mHealth” (mobile health) is in-
tegrated into a wide range of health services which are offered on portable mobile devices. Health apps on
smartphones and tablets are themost popular type of application in this ﬁeld. There are numerous possibilities
for using health-related apps and they range from comparatively simple ﬁtness and wellness apps to applica-
tions providing sophisticated diagnostics and treatment options. The target audience is as diverse as the range
of applications being offered: relevant apps are used not only by patients and insurance companies, but also by
healthcare professionals. Health apps already play an important role in the secondary healthcare market, but
are also gaining importance for the primary healthcare market, where patient services are reimbursed through
statutory (GKV) and private health insurance (PKV).
Overall, various economic and political stakeholders, as well as users – on a national and international level
– see great potential for this new technology for healthcare accompanied by growth in the digital economy.
Hopes of improving healthcare through cost-effectivemeasures are to bemet by implementingmHealth (Becker
et al. 2014). A possible starting point can be measures in the context of prevention, which provide a cost-
effective means for promoting self-help and patient autonomy (Landry 2015, Boulos 2011). As a consequence
of the recently adopted Prevention Act, in Germany, support for health related self-help has been increased,
which also promotes the discussion about mHealth based solutions.
The optimisation of care for chronically ill patients is also being identiﬁed as a possibly effective ﬁeld of appli-
cation. In particular, potential for success is seen for treatment monitoring models and measures to improve
adherence to treatment (Becker et al. 2012). The same applies to post-operative care and rehabilitation. For
structurally weak regions with only few health care professionals, digital solutions may offer support for pro-
viding or receiving care, independent of location (Anderson, Henner and Burkey 2013). On the whole, mHealth
has the potential to improve patients’/insured people’s health literacy which may allow them to exercise their
patient rights more easily.
However, new apps can also confuse users, fail to provide correct information or may create a false sense
of security. So far, risks have only been insufﬁciently studied. Knowledge of hazards and health risks is,
however, essential for weighing up the risks against the beneﬁts. Regarding this latter point, medico-ethical
considerations are also to be taken into account, and these deal with issues of autonomy, participation, privacy
and monitoring in the context of the use of health apps.
2 Problem Deﬁnition
The rapid and enthusiastically greeted spread of mobile technologies in medicine has so far resulted in a pro-
liferation of methods. Many projects are geared to short-term successes and have so far been done without a
long-term strategic orientation. This multifaceted complexity for everyone involved makes it difﬁcult to as-
sess the opportunities and risks, particularly because a solid base of information is currently lacking (Albrecht
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2013, Nurul and Albrecht 2014). The lack of extensive scientiﬁc evidence regarding the long-term beneﬁts of
mobile solutions in the above ﬁelds is often criticised (van Heerden, Tomlinson and Swartz 2012). Existing
studies greatly vary in terms of both methods and content, making a comparison of the results as well as their
transferability to other situations (Free et al. 2013, Free et al. 2013a) and possible reimbursement of costs
more difﬁcult. The new opportunities arising from the technology may equally be underestimated or overes-
timated. Measures which are based on an insufﬁciently valid foundation run the risk of the available control
mechanisms being inadequately aligned. This can adversely affect care (beyond the needs), security (measures
that are too relaxed) or can hamper innovation (measures that are too strict).
Creating a base of evidence may help reduce the barriers for adopting new legislation and facilitate the neces-
sary interdisciplinary cooperation, ultimately improving the quality of patient care. The current lack of a base
of evidence on the subject of mHealth is a global problem. There are only few independent studies, and often,
available personnel capacities are insufﬁcient for meeting the demand for scientiﬁcally sound analysis. This
results in a lack of orientation, which, amongst other things, leads to insufﬁciently adapted legal requirements
for new mHealth technology and thus complicates or misdirects innovations. This also has an impact on Ger-
many as a business location. A market research ﬁrm advises, for example, that mHealth products should only
be developed for the German market with low priority (research2guidance 2015), in part because electronic
prescriptions are not possible, there is a lack of infrastructure for electronic health records, and professional
laws only allow for remote care in a limited set of circumstances.
3 Objective
The aim of the project “Chances and Risks of Mobile Health Apps (CHARISMHA)” was to take stock of the cur-
rent framework for the use of health apps in Germany in the context of efforts made by other EU countries.
The objective was to identify ﬁelds of action for promoting meaningful use and recommend measures to min-
imise risks. The exploration of the ﬁeld needed to include a variety of disciplines (e.g. medicine, economics,
law, ethics, see below). Existing regulations, which are usually not speciﬁcally adapted to the requirements
of mobile technologies, had to be examined via a multidisciplinary approach with regard to their strengths,
weaknesses, opportunities and risks. Using input from various disciplines, potential solutions needed to be
developed, and these are intended to serve as a basis for adapting the legal frameworks and initiating targeted
funding programmes as well as incentive schemes.
4 Method
The study¹ was based on a catalogue of key subjects and questions, which was derived from the general discus-
sion on the topic and supplemented with suggestions from the Federal Ministry of Health (BMG). Answering
these questions required a broad, ﬂexible and interdisciplinary approach, not least of all due to the rapid,
scarcely regulated developments, as well as overwhelming and yet confusing media coverage. Various inter-
faces and intersections between the different specialist disciplines had to be taken into account in order to
uncover and understand the complex dynamics and synergisms/constraints of the existing complex relation-
ships. The work was carried out by an interdisciplinary team of experts.
Each expert worked independently on the particular aspects relating to her or his discipline and used the sci-
entiﬁc methods such as structured literature reviews and other tools. The respective partial results, also con-
taining initial conclusions and recommendations in addition to the analysis, were immediately made available
to all team members. In ﬁve coordination workshops, existing results were presented and comprehensively
discussed in order to adequately consider the relevant interfaces and to close any gaps in the content. Smaller
teams were formed to work intensively on speciﬁc overarching issues. Conclusions and recommendations were
jointly discussed and coordinated.
The results were summarised in a preliminary ﬁnal report and made available to various stakeholders with an
invitation to comment within four weeks. At the beginning of the project, the representatives were invited
and informed about the planned stock taking and were invited to participate in the comment phase of the
project. The feedback was collected and its relevance to the report was jointly evaluated by the experts, with
¹ Chronological sequence: the study period spanned eight months, beginning on 15/08/2015 and ending on 15/04/2016. The
study was drawn up 03/02/2016 and released for the four-week comment period, beginning on 08/03/2016. A total of ﬁve
consultation workshops were held at four-weekly intervals. The ﬁnal report was ﬁnalised on 15/04/2016 after processing the
feedback.
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errors corrected in the report and relevant aspects being included in the conclusions. Lastly, the report was
ﬁnalised and published as a result. Available comments on the study are provided on the project’s website
(http://www.charismha.de/).
5 Financing
The study was funded by the German Federal Ministry of Health (BMG) under the grant number ZMV I 1 -
2515FSB503. The total amount was EUR 103,690.30, which takes into account the own contribution of the
Medizinische Hochschule Hannover (Hannover Medical School).
6 Structure
The results are presented in a chapter structure as explained below.
The ﬁrst section (Chapter 1, “Introduction and Deﬁnition of Terms”) ﬁrst establishes the subject of electroni-
cally supported health (eHealth) and the contribution made by mobile technology (mHealth) in this context.
Then, the multifaceted concept of health apps is set out, taking into account the underlying technology and
the stakeholders involved (manufacturers, users). The following section provides a description of the market
(Chapter 2, “Health Apps and Market”). Policy frameworks are described in Chapter 3 (“Health Apps and Politi-
cal Framework”). Chapter 4 analyses general challenges arising from the use of this technology with regard to
care, with a special focus on the challenges arising from the use of apps in (rural) care settings and from the
requirements of speciﬁc user groups with special needs, such as the chronically ill (Chapter 4, “Health Apps
and Challenges”). In the subsequent chapters, the greatest potentials for individual ﬁelds of application in
the context of prevention (Chapter 5, “Health Apps and Prevention”), diagnostics and treatment (Chapter 6,
“Health Apps and Diagnostics and Treatment”), as well as (healthcare) research (Chapter 7, “Health Apps in
the Context of Research”) are worked out in detail. After describing the opportunities arising from the use of
health apps, the risks are considered in Chapter 8 (“Health Apps and Risks”). Here, in addition to discussing
the concepts of damage, hazards and risks, risks arising from the use of apps in a medical context are con-
sidered and assessed for all user groups (the health-conscious, patients, professional users). Ethical aspects
users and manufacturers are confronted with are described in Chapter 9 (“Health Apps and Ethics”).
The subsequent chapters describe the legal frameworks in relation to the demands of data protection and lia-
bility (Chapter 10, “Health Apps and Data Protection”), as well as regulatory requirements and legal provisions
(Chapter 11, “Health Apps as Medical Devices”).
In particular, statutory health insurance companies operate in a very rigid legal framework and must comply
with multiple regulations in order to guarantee healthcare. To manufacturers of health apps, this market is
very appealing. Offers that are reimbursed/funded by insurers beneﬁt those who are insured. Therefore, a
separate chapter is devoted to the analysis of the market situation, the reimbursement possibilities and the
effects and incentives for statutory and private health insurance: Chapter 12 (“Health Apps in Statutory and
Private Health Insurance”) tackles the evaluation and analysis of health apps offered by private and statutory
health insurance. The speciﬁcs to be considered in this context, as well as the presentation of reimbursement
methods of apps by the payers are looked at in particular here.
Due to the low prerequisites for developing health apps and the low thresholds for access to the market through
simple cross-border sales processes, users are confronted with a highly dynamic and scarcely regulated market
situation. In the subsequent chapters, guidance for patients/insured persons (Chapter 13, “Orientation for
Users of Health Apps”) and professional users (Chapter 14, “Orientation for Professional Users of Health Apps”),
as well as for manufacturers (Chapter 15, “Orientation for Manufacturers of Health Apps”) is compiled, taking
into account the insights gained previously.
Sections of each chapter contain conclusions naming possible ﬁelds of action for policymakers and stakehold-
ers in the health care sector and highlight options for actions and recommendations for further actions based
on the ﬁndings for the respective topics.
7 Summary
The presented work is meant to provide insights into current developments and trends with respect to the
use of mobile health apps. A special emphasis shall be placed on the areas of prevention, diagnostics and
therapy as well as healthcare in general, for example regarding the care for patients with chronic conditions,
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elderly people or rural populations. Other important areas of interest are the identiﬁcation of risks that may
arise from using health apps, especially in the context of data protection and data security. An appraisal of
the practical, as well as regulatory hurdles one may encounter when using health-related apps in various use
cases is given along with a description of points where adaptations to existing regulations might be advised.
In addition, the ethical implications of using health-related apps in various contexts are outlined. In order
to better respond to the needs of individual stakeholders, i.e. patients as well as medical professionals and
developers of health apps, an outline of possible ways to support each of these groups is provided. Finally, the
closing summary chapter describes important areas where action may be advised to be able to eliminate the
identiﬁed hurdles, which may be technical in nature, but may also be due to legal or ethical concerns. This
aims at minimising potential risks for all those who are dealing with health related apps, but may also serve to
provide insights into how relevant uses of mobile technologies in health contexts can be promoted.
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1 Introduction
1.1 Always There, Immediately Available
Mobile technologies integrate seamlessly into our daily lives. They are available in many different forms. TheirSee Chapter Rationale.
Urs-Vito Albrecht use characterises our age of accelerated interpersonal communication and information transfer. Nearly a quar-
ter of a century after the presentation of the ﬁrst multi-functional mobile phones, it is now natural to reach for
devices which at the time were considered visionary: smartphones, tablets, smartwatches and data-providing
glasses – the range of such products grows as technology becomes increasingly smaller and more networked.
The success of portable mini-computers is due to the convenience they offer to fulﬁl various tasks. Barriers to
use are low and the sales and marketing of corresponding software, known as “apps” (short for “applications”),
are easy. Providing services supported through mobile technology is now even easier than it was at the begin-
ning of the millennium. This immensely expands the scope for innovation with manageable ﬁnancial risks for
the developers and leads to a wide range – including in the ﬁeld of health.
Used responsibly, mobile technologies can support the design of modern and equally resource-saving health-
care offerings in the area of medicine. They might even have the potential to contribute to improving the
performance and quality of care, especially in the care of chronically ill or elderly persons. Prevention and
promotion of health also offer wide areas of application.
Indisputably, there are great opportunities in all of these areas, which are taken up enthusiastically by many.
However, the integration of mobile technology into all areas of life also carries a number of risks. Many users
turn to the devices with relatively little consideration and are not aware of the potential dangers that can
result from using them, especially in highly sensitive areas such as health and medicine.
The present study extensively deals with the issue of the use of mobile technologies in medical and general
health-related applications and looks at it from various perspectives. Opportunities and risks are analysed
and possible options for action pointed out for all involved. To do this, medical, technical, but also legal,
ethical and economic issues are fundamentally analysed. The study deals with the conception, creation and
application of mHealth-based solutions and health apps in particular.
1.1.1 Mobile Health (mHealth)
Mobile health, also known as “mHealth” , is a new, dynamic and expanding ﬁeld of healthcare, which producesSee Chapter 1. Introduction
and Deﬁnition of Terms¹.
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innovations in short cycles and is constantly changing. Currently, it is still exploring its own boundaries,
meaning that there is still no consensus on a generally applicable deﬁnition of the term. Ultimately, mHealth
can be understood as healthcare electronically supported by mobile devices.
“mHealth” is closely related to the ﬁelds of “telemedicine” and “eHealth” and a clear delimitation is difﬁcult.
The fundamental difference is the way in which the corresponding services are provided. “Telemedicine” is
often used as a general term to summarise communication technologies (usually-audiovisual). This is under-
stood as a technical bridging of the distance between healthcare professionals and those affected, comprising
the spectrum of medical services (diagnostics, consultation, therapy). “eHealth” (also known as “electronic
health”) is even broader and includes additional health-related services provided by means of modern infor-
mation and telecommunication technologies. According to the WHO deﬁnition, “mHealth” extends the range
of functionalities by adding a mobile component. Here, healthcare is provided via any type of mobile de-
vice offered, using devices ranging from simple mobile phones through smartphones, phablets and tablets to
wearables and other portable devices that can be used in the area of health (Kay, Santos and Takane 2011).
¹ Currently, Chapters 1–15 are only available in German.
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1.1.2 Health Apps
The mobile hardware (miniaturised, programmable, performance-optimised and energy-optimised devices) is
the basis for apps. This is software that creates countless application possibilities on these devices. Apps turn
these devices into specialised tools for speciﬁc tasks. “Health apps” are those that are intended for use in
health and wellness, but also in the ﬁeld of medicine. They can be used to prevent or mitigate diseases and
their consequences (prevention), but also for providing medical, care and other health related services. They
can also support measures that aim at strengthening health (health promotion).
Apps address the entire spectrum of “health” as covered in the WHO’s deﬁnition of the term. This deﬁnition
describes health as a “state of complete physical, social and mental well-being and not merely the absence
of disease or inﬁrmity” (WHO 1948). Accordingly, “wellness” offerings, whose objective is to improve and
strengthen health based onmeasures aimed at promoting health, also fall under this deﬁnition. This is relevant
for mHealth. Applications that speciﬁcally involve the detection, cure or alleviation of disease, suffering and
bodily harm, are attributable to “medicine”. This differentiation becomes relevant when an app crosses the
boundary between a supporting wellness app and a medical device – with all the resulting consequences for
those involved. This will be discussed in greater detail below.
Throughout the report, the previously outlined terms serve as application-related guidance. Due to the rapid
developments in the area of mHealth, continuous adjustments and enhancements will be needed. Existing
projects and efforts, which serve as a basis for deﬁning terms and performing fundamental research in the
context of mHealth on national and international levels, should therefore be encouraged and new ones estab-
lished where necessary.
1.2 Current Market Situation
1.2.1 Mobile Technology and Its Dissemination
Currently, two companies dominate the mobile operating systems market: Apple with its iOS operating system See Chapter 2. Health Apps and
Market.
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and Google with Android. At present, these two players hold 97 % of the market, with Android leading the
market. The success of these mobile systems is based on the sales and marketing concepts for the software
(“app stores”), enabling low-threshold access to the market for both manufacturers and users. This is reﬂected
in the number of apps available. Even if only the two categories “Medicine” and “Health and Fitness” are
considered, there are between 80,000 and 90,000 apps, depending on the counting method.
Themarket for mobile devices is more fragmented. iOS-based devices are developed and distributed exclusively
by Apple, while there are numerous manufacturers for the Android system. For Android, manufacturers use a
variety of hardware components and customise the operating system to a varying degree. This allows an inﬁnite
range of combinations of hardware and software. However, this diversity can also lead to problems if there are
different equipment standards and comparisons are difﬁcult.
Those supplying the operating systems deliberately provide only a basic set of functionalities and apps along
with their software. The sales model is primarily designed to provide third parties with a platform for their
own developments. The corporation also earns money from the distribution of this software, be it by granting
licences for the provision of the necessary development environments, a proportion of the proceeds from the
sales of apps or indirectly through the sale of equipment.
Manufacturers of health apps come from varied backgrounds. The spectrum of developers and providers ranges
from private individuals through privately organised companies and institutions to (health) insurance com-
panies. Within this study, mainly private companies and developers were identiﬁed. Public and private health
insurance providers, as well as other types of manufacturers and suppliers of apps, for example, public insti-
tutions or non-proﬁt organisations, played a relatively minor role.
1.2.2 Economic Aspects
High download rates are only achieved by few apps and their manufacturers. Rarely do the proceeds from
the sale of the software cover the costs or allow for a proﬁt. Currently, only few app providers are able to
implement viable and proﬁtable business models that are solely based on the sales options (paid apps, in-
app purchases, subscriptions) provided by the stores (research2guidance 2015). A following disparity can be
observed: Developing an app for the healthcare sector, particularly one of high quality, is expensive. However,
customers in the stores are often unwilling to pay substantially more for health-related apps than they would
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pay for apps of other categories. In the evaluation carried out in the context of this study, the number of free
offers outweighed that of the pay deals by far. Nevertheless, for example, of the free offers available for the
Android platform, with between 20 % (category “Medicine”) to 40 % (category “Health and Fitness”), only
relatively few apps provide in-app purchases (purchase/unlock additional content and features from within
the app).
Often, indirect ways of ﬁnancing the development costs are found, as well as ways of generating proﬁts. These
include, among others, providing advertisingwithin the apps. In addition, data can be handled as a “currency”,
speciﬁcally with regard to initially free offers, as proceeds are obtained by selling the data. Both have to be
viewed critically, particularly in sensitive areas such as health.
In the long term, ﬁnancing apps solely through themechanisms of the stores, whichwere designedwith generic
apps in mind, is not economically feasible for all types of applications or manufacturers of apps in the ﬁeld of
medicine and health. Another problem is that, based on this, even for medically useful applications, the burden
of ﬁnancing these applications, rests on the shoulders of the users – apart from some pilot projects funded
through health insurance funds/companies and other payers (Terry 2015). Therefore, for the future, it would
be desirable to make provisions for mHealth solutions and health apps that have proven their efﬁcacy to make
these reimbursable for those who are insured. This could relax the situation for both users and manufacturers
and make a signiﬁcant contribution to the provision of high-quality apps.
1.2.3 User Requirements
According to current ﬁgures, 63 % of the German population already use a smartphone, so the number of
(potential) users of health apps is large (Weicksel and Pentsi 2015). Their use extends through all layers
of the population. The spectrum of users covers various age groups and levels of professionalism, ranging
from healthcare professionals with professional demands through those interested in health, to acutely or
chronically ill people.
Younger people are more likely to have access to relevant devices than elder people, but the rate of those
who use mobile devices and apps (Weicksel and Pentsi 2015) is also increasing among those over the age of
65. Although all these groups can potentially beneﬁt from using health apps, apps for certain user groups
were under-represented in our analysis. Only a few apps take into account the needs of physically, mentally or
cognitively impaired users. Barrier-free design of an app is something of an exception.
The expansion of funding programmes that support the development of barrier-free and innovative mobile ap-
plications could change the landscape of apps being offered. Care should be taken to promote access to mobile
technologies in general as well as in the context of health, in particular in certain parts of the population (e.g.
the elderly, socially disadvantaged, etc.). This can be done by the provision or partial ﬁnancing of equipment,
training materials, and through appropriate programmes, information campaigns, etc. Equal participation
also requires appropriate skills. In the long-term, however, the necessary skills and knowledge should already
be part of school education.
1.2.4 Areas of Application and Features Provided
There are health apps available for a wide variety of needs. In the health related sections of the stores, apps
of various sub-categories, such as health-related reference books, patient diaries or ﬁtness and wellness apps,
are provided. Apps for informational purposes are in the foreground. These include references, teaching and
learning materials and news apps. Medical professionals as well as sick people or health conscious users are
being addressed. Generally, apps that provide support in health issues play a major role, in particular in the
context of chronic diseases.
However, health apps for genuine diagnostic or therapeutic purposes, possibly touching on the area of medical
devices, are rare. In the random sample, which was examined in the course of this study, not a single such app
of this kind was found.
The expectations and demands placed on health apps vary. Everyone involved has different desires, skills,
knowledge and requirements, as well as different ideas about how they should be implemented in a health app.
The apps that are tailored to the needs of users of the target group are the successful ones. Thus, these needs
must be determined and investigated.
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1.2.5 Restricted Market Overview
The market is confusing due to its size, dynamics and little regulated organisation. The monitoring of the
market is made more difﬁcult by the lack of transparency on the part of the participating providers (app man-
ufacturers as well as platform operators). Users who want to identify a health app that matches their ideas
sometimes struggle when it comes to orientation. There are various reasons for this. In the ﬁrst place, in-
adequate or incomprehensible store descriptions (in terms of content and language) that do not provide the
particulars of the functionalities and content offered can be confusing. Also, information is often lacking with
respect to potential limitations, data protection, or even the manufacturers themselves. In part, this may be
due to the fact that to date, on the part of the store owners, the distribution of health apps via the stores is
largely subject to the same conditions that must be met for other store categories.
Efforts should be made to make it obligatory for manufacturers to provide information about the content and
functionalities of health apps, similar to what the store operators already require in the context of age classi-
ﬁcations of apps. Equally, manufacturers should be obliged by the store operators to provide full information
on data protection, as well as on the contact data and content of the apps and their sources of funding.
1.3 Political Framework
According to the European Commission (2015), mHealth – and therefore health apps – have the potential to See Chapter 3. Health Apps and
Political Framework.
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drive the health sector towards decentralised, patient-centred healthcare which promotes the right to self-
determination. mHealth can support European values of solidarity, universality and equality, as well as the
European principle of freedom of movement. At the same time, it can stimulate economic growth and support
health system innovation.
In this context, the current efforts of the European Commission seem to focus on innovators and decision-
makers in order to create an innovation-enabling environment across the EU that is driven by the private sector.
Various instruments are employed here, such as public consultations, the development of codes of conduct and
guidelines, the promotion of frameworks and standards for interoperability, the revision of the medical device
guidelines, and the further development of the consumer protection directives to include digital aspects. By
contrast, the German focus appears rather narrow, with an emphasis on strengthening state-managed projects,
such as digital discharge records or the electronic health card, which appear technology-centred as opposed
to solution-oriented.
Comprehensive efforts are needed to prevent the loss of connection to other nations’ eHealth sectors. The
digitisation of the German healthcare system is a complex, large-scale project that not only affects healthcare
provision, but also research and business. Investments come from both public and private funds. Projects of
such a magnitude are prone to frequent and signiﬁcant budget and deadline overruns, beneﬁt shortfalls, and
increased viability risks. This has relevant implications for both Germany’s national eHealth strategy and its
position as a business location for eHealth companies and health-app manufacturers.
1.3.1 Strategy
One requirement for a fair supply of health apps is the creation of an adequate infrastructure (nationwide
coverage with high speed broadband internet) as well as the assurance of a good public digital and health lit-
eracy. As future technological developments are difﬁcult to predict (Brynjolfsson and McAfee 2014, Naughton
2012), it is important that Germany develops a robust but adaptable eHealth strategy (Beinhoecker 1999). It
should focus on functions and results (e.g. “digitisation of communication”), rather than adhering to certain
approaches (e.g. “electronic discharge letter”). Speciﬁcally, that means, for example, that ﬁnancial incentive
systems should not only be limited to certain technological approaches, but a stronger focus should be placed
on cross-application regulations. Clear rules are also needed for dealing with data that will be collected or
processed by apps and mobile devices. As an example, the need for quality standards for applications beyond
the Medical Devices Act, the data of which will be used for health-related research, should be mentioned here.
Also, the timely development of adapted screening criteria for the application of predictive models based on
the user data by apps is required.
1.3.2 Promoting Internationalisation
To take into account the cross-border nature of eHealth and mHealth, a stronger emphasis should be placed
on internationalisation. For this purpose, the expertise and the development advantages of internationally-
oriented organisations (e.g. ISO, IHE, HL7) would be useful here in order to develop internationally com-
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patible standards. This would save time and money, which would otherwise be invested in largely redundant
work, serving to establish better international compatibility (HL7 Germany e.V. 2015), which is important for
the full exploitation of the potential of mobile technologies. HL7 currently has four active working groups
(HL7 2016) dealing with subjects of standards development for safe mHealth apps, programming interfaces for
health information, security and privacy standards and SMS usage for health applications. IHE is presently
developing transaction deﬁnitions to facilitate data exchange between mobile devices and existing databases
(IHE 2016).
1.3.3 Organisational Structures
In the current legislation, some of the necessary processes, concepts and goals are deﬁned ambiguously or
deﬁciently, which can lead to signiﬁcant problems regarding transparency, outcome measurement and project
coordination. Insufﬁcient ex-ante planning and preparation result in increased risks of cost and schedule over-
runs (Flyvbjerg 2014). Ideally, clear and binding interoperability catalogues, standards, and understandable
deﬁnitions should be adopted prior to the development of concrete infrastructures and applications (e.g. elec-
tronic patient records). Since until now technological innovation cycles progress faster than standardisation
processes, even in countries with advanced digital health systems, standardisation remains a major challenge
(Anell et al. 2012, Barbarito et al. 2012, Boyle 2011, Chen et al. 2014, Chevreul et al. 2010, Edwards et al.
2010, Lai et al. 2013, OECD 2013, Rice et al. 2013, Rolnick 2013, Steel et al. 2012, Strandberg-Larsen et al.
2007, Vuorenkoski et al. 2008). However, a benchmark of the European Commission clearly shows that Ger-
many is below average in Europe in terms of the adoption of eHealth, which also includes the dimensions of
infrastructure and integration (European Commission 2014).
The organisational structures should be arranged in such a way that they provide sufﬁcient protection against
the inﬂuence of individual interests and allow processes transparency. In this way, key players are not ex-
cluded from relevant development processes. If this is not taken under due consideration, socially inefﬁcient
outcomes, public mistrust, and reduced acceptance of results (Dixit 1998) can ensue. Speciﬁc precautions to
improve supervision can help minimise these risks, including process transparency, and clear selection criteria
for external consultants, as proposed by HL7 Germany e.V..
1.3.4 Learning Healthcare Systems
The potential of digital technologies should be exploited more fully for the purpose of research promotion.
Extensive discussions are currently taking place about how the future of “learning healthcare systems” could be
designed. Health apps can be seen here as a key pillar for obtaining information (Foley and Fairmichael 2015).
The development of a roadmap for the transformation of the German healthcare system towards a learning
organisation structure based on emerging digital infrastructures is recommended.
1.3.5 Reducing the “Digital Divide”
The “digital divide” of the usage potential of modern health technologies among citizens must be reduced.
Owning a smartphone alone is not sufﬁcient to take meaningful advantage of health apps. Rather, the exis-
tence of a sufﬁcient infrastructure, as well as digital and health literacy (i.e. the ability to use digital appli-
cations properly and to critically evaluate health information) is of importance. The provision of equitable
access to eHealth solutions and the promotion of eHealth literacy of German citizens are societal tasks that
require the concentrated efforts from various ministries, public authorities, and organisations.
2 Opportunities and Challenges
The range of health apps is as varied as the users and their needs. The description of characteristic functionsSee Chapter 4. Health
Apps and Challenges.
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is just as difﬁcult as deﬁning the role that they can or should take in healthcare. Whether an app does more
good or harm is difﬁcult to judge.
Apps related to health should be consistently differentiated according to the purposes, applications and user
groups. This would make the classiﬁcation easier as to whether they are rather marketing tools with no added
value for the health of users or whether they bring a real beneﬁt. Methods and tools are needed to distinguish
between the useful and the less useful offers.
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2.1 Having Potential, But Lacking Evidence
The potential is established in particular with regard to possible cost savings and quality improvements. Health
apps are potentially suitable to support the self-management of chronically ill patients effectively and to
increase adherence and compliance. The use of apps in lifestyle-induced diseases such as diabetes mellitus
(type 2) is at the forefront here. A high therapy adherence, which can be supported by apps, can prevent
costly treatments and hospitalisations in many chronic illnesses (Robert Koch Institute 2015).
For persons who are hard to reach using conventional ways, the different functions and application areas of
apps have the potential to provide support for their respective problems. Especially for persons with various
disabilities and functional limitations (health) apps can open up new possibilities and help them cope bet-
ter with the handling of their health problems and live more independently. This does, however, require an
appropriate, e.g. barrier-free, design and a general good usability of the apps. It is also important that the
apps address the different needs of the patients, as well as their requirements. Currently, apps that adequately
implement this are rare. Usually, it is more a case of addressing the needs of the general public. To improve the
situation, incentives should be created for manufacturers to provide high-quality services for smaller groups
as well, for which, however, a big beneﬁt can be expected.
Another area where health apps can probably play an important role is providing care for the rural population.
Here, apps, together with other telemedical offers, can potentially help tackle supply bottlenecks. It may
be helpful to build on the experiences of other countries that have healthcare systems that are similarly well
developed as the German one.
In the long run, however, the potential of apps for healthcare can only be exploited if they can be integrated
in the existing care and compensation systems. Apps for which this is not possible will not be able to establish
themselves within care processes.
Although the description of the potentials is plausible, there is little scientiﬁc evidence available, for exam-
ple, in the form of study results, which may be due to the fact that classical scientiﬁc practices are not very
suitable in this case. The required (longer) period of investigation is often diametrically opposed to the high
development dynamics of the apps to be evaluated and the mobile devices they run on. This explains why there
is so far only little evidence for the cost-reducing potential of health apps.
2.2 Promoting Effectiveness and Expanding Infrastructure
The usability of health apps mentioned above is a decisive factor (Mival and Benyon 2015; Dyer et al. 2012),
which can contribute to the effective use of health app in healthcare. Improving and expanding telemedical
infrastructures and ensuring good compatibility between the various systems are equally important.
To transfer the potentials of mHealth and health apps into reality, the development and expansion of telemedi-
cine infrastructures should be encouraged. One possible contribution would be to clarify the remuneration of
healthcare providers in telemedical care projects. Here, representative organisations of healthcare profession-
als, as well as the various professional societies are called on to get involved. Once the remuneration is cleared
up, health apps will be employed more actively by doctors. As a result, this may also mean that patients use
appropriate apps more often – and to the beneﬁt of their health. The health professionals can set an example
at this point.
2.3 Ensuring Quality and Security
The search for high-quality health apps is a challenge for both patients and health professionals. Without as-
sistance, it is difﬁcult for them to orient themselves. High-quality (health) apps that provide valid information
and fulﬁl their purpose reliably and safely are more the exception than the rule.
Laymen and professional users are barely familiar with the criteria that they can apply to identify secure and
useful offers. This can be remedied through appropriate guidance, which will be addressed in more detail in
other parts of the report. Framework conditions and quality requirements that can be used to evaluate the
quality and security of apps should be formulated in these guidance documents.
It would also be desirable to determine the speciﬁc needs already in the planning phase before starting the
implementation. Furthermore, the targeted user groups such as patients and healthcare professionals should
be involved in the planning and the implementation. This is the only way to develop health apps, which meet
the demands of those who will use them later.
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3 Areas of Application
3.1 Health Apps in Prevention
Health apps can potentially be used in primary, secondary and tertiary prevention². To achieve lifestyleSee Chapter 5. Health
Apps and Prevention.
Maria Rutz, Darja Kühn
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changes, there are already many offers in the form of “lifestyle” apps. These can raise their users’ health
awareness, primarily in relation to physical ﬁtness and weight loss. In the context of these apps, the largest
proportion of studies that were identiﬁed in the literature dealt with prevention. Here, there was evidence
that the use of apps can have a positive impact on the increase in physical activity, changing diet and weight
control (e.g. Lubans et al. 2014, Glynn et al. 2014, Nollen et al. 2014, Carter et al. 2013). For other areas,
studies are lacking which securely demonstrate the positive impact of apps, for example, for informing about
cardiovascular risk factors or the prevention of cancer. The fact that the use of apps in the prevention de-
creases over time has not been sufﬁciently investigated yet. The majority of studies do not collect data about
precise disease-speciﬁc outcomes, making it difﬁcult to assess the results.
3.1.1 Beneﬁts of App-Based Prevention
The main beneﬁt of apps is to create low-threshold access to health-promoting services. Thus, preventive
lifestyle changes can be initiated for many persons at an early stage, without the health system having to get
involved. Also, due to the technical possibilities, apps have the advantage of being able to make recommen-
dations based on the most recent data (Neubeck et al. 2015).
To make best use of health apps in prevention, the preferences of users must be precisely evaluated and the
users must be enabled to identify effective apps. Both users and experts should be involved in the development
of apps to review the evidence and to recognise risks at an early stage.
3.1.2 Improving Access to Prevention
Studies should pay more attention to different settings and different social groups when evaluating the efﬁ-
cacy of apps in prevention. It should be investigated how to reach persons with an increased risk of disease
and low health literacy in a more efﬁcient way. Costs incurred in the context of using apps must not lead to
disadvantages for speciﬁc population groups. Alternative models for prevention are to be developed here.
In future, an evaluation and structuring of the existing apps and studies in relation to evidence, use and
effects is advisable, as till now, the main focus was on single apps and apps new to the market . There is still a
lack of long-term scientiﬁc studies that evaluate the requirements for apps to make an effective contribution
to prevention.
The use of wearables is increasing. The continuous recording of data via wearables can be used in the preven-
tion of diseases (O’Reilly and Spruijt-Metz 2013). However, it must also be studied to what extent self-tracking
can intensify fears of illness (“cyberchondria”).
The range also includes apps that encourage behaviour that is harmful to health (Crane et al. 2015). Strategies
for dealing with this type of “malware” must be found as well.
3.2 App-Based Diagnostics and Treatment
Health apps are offered and used to support diagnostics and treatment, including rehabilitation. Their beneﬁtSee Chapter 6. Health Apps and
Diagnostics and Treatment.
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is that (any) information can be collected, accessed and visualised at any place and at any time (Meng et
al. 2015). This can allow for swift decisions, optimised treatments and cost reduction. For patients, it is
convenient to be able to communicate with their attending medical and care staff regardless of time and place
(Ritchie 2013). For doctors, when providing care, mobile applications offer new means to obtain up-to-date
information about their patients. When using apps in the context of telemedicine care concepts (particularly
in dermatology, cardiology and radiology), it is important to check the validity of the diagnoses and to respect
the legal requirements (the ban on a solely remote treatment of patients, without any direct contact having
taken place beforehand).
² Primary prevention involves among other things education about health risks or early detection screening procedures with
the aim of preventing the emergence of diseases (BMG 2015 and GKV Spitzenverband 2014, page 15 or Article 20 of the Fifth
Book of the Social Security Code (SGB V)). Secondary prevention deals with screening for diseases in the context of known
risk factors. The aim is to initiate the “earliest possible treatment” (BMG 2015) or intervene in diseases in early stages (GKV
Spitzenverband 2014). Tertiary prevention attempts to reduce the consequences of an existing illness, to largely avoid their
aggravation or to prevent relapses (BMG 2015). Rehabilitation is also part of tertiary prevention (GKV Spitzenverband 2014).
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3.2.1 Use by Lay People and Professionals
Apps for diagnosing diseases are predominantly used by medical professionals, whereas apps for treatment are
used by doctors and patients alike. In the literature, wearables and health apps used in the care of patients
with neurological disorders are strongly represented (e.g. Lopez et al. 2014, Zhao et al. 2015). The majority of
apps for use by lay people and professionals deals with skin diseases and cardiovascular disorders. Health apps
have the potential to be useful tools in healthcare because they support the presentation of medical ﬁndings,
communication processes, and the aggregation of data, thus speeding up the process of making a diagnosis.
3.2.2 Success Factors
For users, more easily communicating with their physician and the corresponding practice is of primary impor-
tance (e.g. Ritchie 2013). They also have high expectations regarding safety and want app recommendations
from doctors or health insurance providers. Collaboration between app developers, users and those providing
treatment is necessary, as is regular adaptation of the user interface to the needs of the users.
3.2.3 Functional Areas in Diagnostics and Treatment
Many apps have identical (isolated) feature sets (Arnhold et al. 2014). For the future, a combination of vari-
ous functionalities in one app (awareness-raising and education, support for lifestyle changes, strengthening
health-promoting behaviour, management of diseases, etc.) would be useful. In particular as regards the data
transfer, it is not entirely clear whether apps fully exploit the existing technical possibilities. Further studies
on the quality of data transmission, as well as the advancement of the technology, are necessary.
Health apps for supporting self management are gaining importance (e.g. Chomutare et al. 2011, Baron et al.
2012). These apps are meant to accompany persons of all ages in their daily lives and improve communication
between healthcare providers and patients. This therapeutic ﬁeld of application has been studied frequently.
It remains to be seen whether the use of apps can lead to sustainable improvements of self-management.
Especially elderly persons, who are often unfamiliar with the technology, may not be able to take full advantage
of the beneﬁts apps offer for healthcare. The competences of elderly people should be promoted and the
apps themselves developed so that they can be used by elder generations. Valid evidence is lacking as to the
extent to which apps are already integrated in healthcare and what the potentials for elderly persons are. Also,
existing apps often do not fully implement existing guidelines for self-management.
The healthcare for migrants represents a further area of application for apps. Communication between doctors
and migrants can be facilitated with the help of translation apps. However, the preferences of the migrants
should still be systematically recorded to be able to provide better healthcare services.
3.2.4 Motivation Through Apps
The wearable market is expanding, but there are only few studies dealing with the use of this technology for
diagnostics and treatment. It can, however, be assumed that the costs incurred and possible measurement
inaccuracies can be an issue.
Little is known about reward systems that lead to an improvement in the adherence by using health apps in
therapy. It is also unclear what factors need to be taken into account for apps used in the short term, and
what factors are important in the context of long-term use. There is just as little information on the use of
multiple apps for the same purpose, so-called app-hopping. No information on this topic was found. Therefore,
studies on the consequences of and dealing with different pieces of information should be carried out here. It
is also important that, in the context of diagnostics and treatment, there are few gender-speciﬁc apps or apps
intended for socially disadvantaged groups in the context of diagnostics and treatment and that apps for these
groups, just like various ﬁelds of application (settings), are not adequately considered by existing studies.
In principle, apps offer the chance for participation and patient involvement. They can support different
phases of the care process within healthcare. Transparency must be established both with regard to app devel-
opment (Cantudo-Cuenca et al. 2014) and intended use. Users must be able to clearly identify the objectives
and intended areas of application of the apps. To avoid incorrect uses, the limitations of the apps should be
clearly speciﬁed. In cases of damage due to incorrect implementation, the issues need to be resolved in a rapid
and professional manner.
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3.3 Health Apps in the Context of Research
Apps are becoming increasingly popular in the research context. In addition to the evaluation and validation ofSee Chapter 7. Health Apps
in the Context of Research.
Urs-Vito Albrecht, Ute von Jan,
Oliver Pramann & Heiner Fangerau
existing app-based interventions and treatment pathways in healthcare, they create new possibilities for data
collection in clinical trials. Here, apps can potentially help save resources and provide assistance in acquiring
data.
3.3.1 Possibilities of Apps in Research
Integrating apps into clinical research can bring beneﬁts for all involved. For the participants, for example,
the number of absolutely necessary visits to the study centre can be reduced when using an app-based study
design. Both researchers and participants beneﬁt from the largely simple and convenient data acquisition.
This can lead to a more complete data pool, which is also easier for researchers to evaluate. In addition,
with the help of research apps, parameters can be recorded both selectively and continuously, which could
not have been recorded – or at least not to the same extent – through conventional approaches (Albrecht,
Pramann and von Jan 2013). There are also advantages with regard to the recruitment or inclusion of larger
study populations. Using app-based approaches, it is also possible to recruit participants who would have been
excluded earlier, e.g. due to geographical distance. Caution is advised in this approach, however, in terms of
attention to inclusion and exclusion criteria, if the app used represents the sole route of contact to the study
centre (Albrecht and Pramann 2014).
3.3.2 Challenges of App-Based Research
Irrespective of the chosen research approach – be it an evaluation of existing solutions or app-based data col-
lection – a number of challenges must be considered if apps are to be accepted in this context. This affects
both basic scientiﬁc and technical areas, but in particular data protection, data security and ethical as well
as regulatory matters (Friend 2015, Albrecht, Pramann and von Jan 2013, Reiss 2013, Albrecht and Pramann
2014). Already at the planning stage, it should be assessed whether an app should be classiﬁed as a medical
device, with all ensuing consequences. However, both the developers and researchers involved are often not
sufﬁciently aware of this. Guidance documents should be developed that serve as the basis for future devel-
opments.
3.3.2.1 Standardisation of Research on and with Apps
Designs of studies performed on or with apps are usually just as little standardised as the apps used in them.
Apps with the sole purpose of acquiring data, without having an inﬂuence on it, will pose little risk. However,
when dealing with the evaluation of app-based healthcare approaches, the comparability of the results to other
studies suffers. Given the fact that apps have to demonstrate their effectiveness and applicability if they are
to become an integral part of medical care, this is not acceptable. It would be desirable to apply standards
similar to those used for pharmaceutical products here as well (Wetter 2016).
For apps used as a research tool (dedicated research apps), there are publications on approaches to help with
standardisation. For example, the “ResearchKit” (McCarthy 2015, Albrecht 2015) presented by the Apple Group
in 2015, like other libraries following the same thoughts, offers standardised components, which can be used
to design relevant apps. These libraries must, however, still establish themselves and some are only available
to certain user groups or limited to a single mobile platform.
3.3.2.2 Scientiﬁc Standards and the Everyday Reality of Users
The much-requested evidence of the effectiveness need not be identical to the actual beneﬁts of health apps
or the measures concealed behind them. The result of the evaluation depends on the selected study design
and the setting in which it is used. An existing “evidence” for a measure or an app means that a statement can
be made that meets the scientiﬁc quality criteria of objectivity, reliability and validity. Many details of what
can be transferred to the user’s real life, however, typically differ from the standards used in the study. On the
other hand, a lack of evidence does not fundamentally exclude the usefulness of the app.
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3.3.2.3 Ensuring equal access, avoiding bias
When employing scientiﬁcally sound methods, there should be awareness of factors potentially leading to a
bias even before the study starts. In particular, for app-based studies that usually take place under conditions
that are hard to control, there may be a selection bias for the sample if certain population groups are under-
represented. This bias can result from the exclusion of those who have no access to the proper equipment or
are simply unable or unwilling to use the technology (Kim, Briley and Ocepek 2015, Smith 2013). If there is no
guarantee that the broadest groups of people can participate, the results of the study are difﬁcult to transfer
to the population as a whole. Ideally, adequate “participation equality” (here in terms of representativeness
and equal participation) can be achieved by ensuring access to the necessary equipment. Measures that allow
those who are not familiar with an app to use the required technologies (digital literacy) might also prove
helpful.
Considering the currently available evidence (or its lack), a further analysis of what is going in the world of
app-based medical research is urgently needed. There are only few studies that comprehensively assess both
the positive and negative potentials, including ethical aspects, of using mobile technologies in research.
In future, given the continuous technological advancement various adjustments will be needed to ensure the
necessary balance between technical innovations on the one hand and their scientiﬁcally correct and ethical
use on the other hand, in the area of research.
4 Risks of Health Apps
Undisputedly, the use of apps in all health-related areas carries a number of risks in addition to the obvious See Chapter 8. Health Apps and
Risks.
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opportunities. These can relate both to an application’s efﬁcacy (including any adverse effects) or the lack
of thereof (not achieving the desired effect). Both can have lasting consequences on health – especially for
the sick persons. Overall, the question is which damages and hazards exist and what risks can be derived from
them for the users, and possibly for their environment.
4.1 Risks, Hazards, Potential Damage
For any use of health apps, hazards must be eliminated and risks minimised to reduce potential damage. The
scientiﬁc literature describes different hazards that may arise from the use of apps in the context of health.
While data protection violations are often reported there has been so far little evidence of real damage to
health caused by health apps. According incidents make their way into the daily press if at all.
However, with the necessary caution, conclusions by analogy can be drawn based on experiences in the ﬁeld
of medical devices. Hazards may thus arise from a number of sources: on the one hand, malfunctions (Kemnitz
2007) can potentially trigger damage both in the apps themselves (incorrectly implemented functionalities)
and in the devices on which they are used. On the other hand, incorrect or misguided use (use-error, see
Israelski and Muto 2012), for example due to design problems of the app in question, can be problematic. This
can also occur if the app is used without being suited for the respective use case or if the requirements of
speciﬁc usage scenarios were not given due consideration.
More importantly, apps bundle information and make it accessible. Therefore, misinformation distributed via
an app represents a relevant source of danger. If the information is used as a basis for decision-making, incor-
rect diagnoses (in terms of an incorrect assessment of the disease), as well as potentially incorrect treatments
(incorrect treatment as unsuitable, not sufﬁciently effective, or excessively performed treatment) can be the
consequence. Both incorrect diagnoses and mistreatment pose a signiﬁcant damage potential for the health
of users.
4.2 Risk Reduction
Various measures are conceivable in order to effectively counter the risk potential of health apps, which apply
at different stages of the life cycle of an app and for various players. Scientiﬁcmonitoring should be considered
in implementing these measures where possible and is to be promoted accordingly. In order to be effective,
these measures must also consider the nature of the dynamic and liberal market. They must also be fast and
easy to implement and it must be possible to customise them to allow for the required ﬂexibility.
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4.2.1 Development
Already during the planning and development of software, manufacturers must perform a risk analysis to iden-
tify and eliminate any hazards in advance. To do this, best-practice methods should be used for developing
software. Instructions can be found in the relevant standards. The development process must be based on
common quality criteria and respect the principles of quality assurance. It is important that the manufactur-
ers provide transparent information about their products. This includes communication on hazards and risks
as well as actual damages. This can be done at a low-threshold in the product information in the app stores
and the apps’ accompanying web pages.
4.2.2 Openly Communicating Adverse Events
In order to be able to soundly assess potential hazards of health apps, however, is not enough to only name
potential risks. Additionally, any incidents that have occurred must be disclosed. However, proof for such
incidents is rarely found. Evidence of damage caused by apps is very rare in the literature; often, there are
at best fragmentary outlines of potential hazards. Rather, for actual problems, there are product recalls by
the manufacturer to be found (e.g. Pﬁzer 2011). Nevertheless, the risks of apps are hardly smaller than for
other measures in the context of health. Here, establishing a low-threshold vigilance system similar to the EU’s
RAPEX system should be encouraged, in which messages about potential and actual damages and adverse ef-
fects can be collected at a central location and provided to the public. The reported information can come, for
example, from the manufacturers, but also the users, who can report events directly. It would be desirable for
providers of distribution platforms (app stores) to be involved in the process, as well, as part of their efforts to
improve the quality of the health apps they offer. On the part of the distribution platforms, mandatory quality
requirements, which – among other aspects – deal with content-related quality, would also be helpful. The
internal review processes already existing on many platforms should be improved to respect these aspects.
4.2.3 Measures by Operators
Operators of health apps are required to take appropriate measures to minimise risks arising from the use of
health apps. In cases of use in a professional environment, it is important to create appropriate guidelines and
process speciﬁcations (Pramann and Albrecht 2014). This may include, for example, binding hygiene standards
for use (cleaning/disinfection of the devices being used), but also processes that serve to protect patient data
on the devices (security guidelines for work equipment or private devices used for work). Providing training
and information is also to be encouraged, and this aims at increasing sensitivity in this context. This does
not only relate to lay users, but also to persons in various professional contexts. Many users are not aware
of potential risks and hazards associated with the use of mobile devices and apps. Therefore, care must be
taken to communicate these to all involved. Awareness-raising campaigns aimed at the general public, but
also at individual user groups as well as providers and developers of apps, can prove helpful. The greater
the understanding of those involved regarding the risks resulting from the use and the ensuing (medical,
legal and ethical) consequences, the sooner will measures that are recommended or mandated either on an
organisational level or by the authorities ﬁnd acceptance.
5 Health Apps and Ethics
Technology-based measurements are not a new phenomenon in medicine. People have been watching theirSee Chapter 9. Health
Apps and Ethics.
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bodies with its functions, limitations and diseases since time immemorial and documenting what they have
measured. The currently booming sector of mobile health applications is based on this need. However, the
new technology has some peculiarities such as the extensiveness and ubiquity of the data collected, which
necessitates not only a scientiﬁc and legal discussion of its opportunities and risks. Rather, a debate about
the moral dimensions of mHealth applications seems necessary. Just as for health and technology, there are
also opportunities and risks to consider on a moral level. In connection with mobile applications that are used
in the context of health, there are many different aspects of medical ethics that need to be discussed.
A variety of approaches dealing with questions related to ethics and the use of mobile health applications is
described in the literature. These reﬂect the diversity of app concepts, areas of application and user groups
and the associated opportunities and risks on the one hand and the shifting focus between addressees resp.
users of apps as well as providers or medical care on the other hand.
The primary issues are the conﬂicts of objectives when usingmHealth. In particular, privacy and transparency,
but also control and autonomy are to be considered in particular in this case. Further ethical issues relate to
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questions of fairness in the use, availability, the participation opportunities, and also the effects the new
technology has on the self-perception of doctors. Often, the challenges are discussed in a general way, e.g. in
relation to patients (data), healthcare professionals and researchers or the requirements for closely connected
application cases, such as people infected with HIV (Labrique 2013, L’Engle et al. 2015, Pérez et al. 2015) or
psychiatric patients (Chan et al. 2015, Glenn and Monteith 2014a, Jones and Ashurst 2013, 2015 Olff, Seko et
al. 2014).
5.1 Privacy and Transparency
Extensive recording of data (as made possible via mobile solutions) offer great opportunities for improving
care. This is among other things a question of transparently using large amounts of data to the beneﬁt of many.
On the other hand, in the context of ethics, data protection and data security, summarised using the keyword
“privacy”, are issues that are equally reﬂected in the legal and technical discussions. Interest in transparency
can be explained by the optimisation of healthcare based on the maximum information possible. The interest
in privacy is based on experiences of stigma, fears of suffering disadvantages and the interest in autonomy
in relation to one’s own sensibilities as well as ﬁndings associated with an individual. The two values are
diametrically opposed and yet users want to achieve both goals, resulting in a paradoxical situation (Bueschel
et al. 2014). Especially in this context and referring to established standards of research ethics, a critical
issue is that for mHealth based approaches anonymity is difﬁcult to implement; it is therefore recommended to
keep data transfers to third parties to a minimum. In light of prevailing standards, providing comprehensive
information about the data collected and how they can be used should be a matter of course. (Carter et al.
2015).
5.2 Ethical Principles
Key principles of medical ethics are the imperatives to do no harm, to observe the autonomy of patients,
which for example includes doctor-patient conﬁdentiality, always to act for the beneﬁt of the patient, and to
distribute healthcare services as fairly as possible. Discussions about the potentials for resolving disparities in
the provision of healthcare service are associatedwith the latter aspect. Additionally, mHealth based solutions
make it possible to more easily reach patients in sparsely populated regions as well as disadvantaged groups
of persons (Nasser and Trevena 2015, Nurmatov et al. 2014, Gordon et al. 2015).
The criteria of reliability, quality, correctness andminimum susceptibility to error – also taken up in other parts
of the present work – can be seen as a minimum requirement from an ethics point of view, and these criteria
can be deduced from the imperative not to harm the patient and the requirement to act for his beneﬁt.
5.3 Responsibility
Points previously mentioned in the context of the use of technology and its resulting potentials and risks
should also be kept in mind. In particular, the loss of interpersonal aspects is up for discussion. There are
fears that, when using technology, personal communication between those involved might be impaired and
that there could be a loss of appreciation and respect (Fangerau and Badura-Lotter 2014). Furthermore, there
is the question of liability if medical technology fails. Responsibility may lie with the doctor, the developer
or the patient. The potentials for misuse of the technology that were already touched upon in the context of
transparency and privacy are also once again up for discussion, in particular if there is a suspicion that these
new solutions for medical problems may be linked to the interests of third parties, such as insurance companies
or the pharmaceutical industry (Fangerau and Martin 2014).
The frequently expressed demand for greater control of mHealth applications follows from this discussion. The
protection of users against possible risks should be a top priority. However, it appears the ethical discussion
is not yet at an end. An investigation that assesses and categorizes the ethical “problems” of health apps with
respect to their risk potential appears to be necessary as well as promising, since risk-related argumentations
can be found at all levels (medical, technical, social, legal, in terms of data protection, on an interpersonal
level, etc.). At the same time, current ethical debates on mHealth should make use of past experiences with
technology developments in medicine and should also take previously successful problem-solving strategies
into account. Some of the questions currently being discussed are similar to ones that have already been
raised in previous contexts. It is important to identify the peculiarities of new developments in mHealth. An
analysis of new risk structures in terms of their premises, their explicit or implicit values and inﬂuencing factors
and dependencies seems expedient for application-oriented research in the context of mobile health apps,
particularly when the aim is to take stock of the ethical situation on a comprehensive comparative scale.
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At the same time, guidelines for the development, recommendation and use of health apps should be consid-
ered, which focus, among other things, on factors such as user autonomy and security, ruling out discrimina-
tion and stigma, and good scientiﬁc practice (Albrecht and Fangerau 2015).
6 Law
6.1 Health Apps and Data Protection
In addition to the moral questions relating to data protection and privacy that were brieﬂy sketched in theSee Chapter 10. Health
Apps and Data Protection.
Oliver Pramann
previous section, from a technical as well as legal perspective, both data protection and privacy remain points
of special interest. It is unclear whether the relevant data protection requirements are always complied with,
which, due to the sensitivity of information, is of particular relevance for health apps. In Germany, data
protection and privacy rules are established in Article 2 (1) of the Federal Data Protection Act in conjunction
with Article 1 (1) of the German Constitution³ (Grundgesetz) and the right to informational self-determination
derived from the verdict of the Federal Constitutional Court (BVerfG) on the Population Census Law (the so-
called census verdict4).
The key regulations are the relevant European data protection guidelines and the Federal Data Protection Act
(BDSG) in Germany, as well as important special regulations in the tenth book of the social code (SGB X),
the Telemedia Act (TMG) and the Telecommunications Act (TKG). Either a legal element of legitimacy from the
fundamental Federal Data Protection Act or a more speciﬁc regulation, where applicable, is required to collect,
process, and use data lawfully. The consent of the respective right holder is also possible here (Baumgartner
2013, paragraph 225) if a statutory provision does not preclude this. The data protection law applicable in
Germany places special demands on information and consent, which are also to be observed for apps.
Apps in particular are often offered in an international context and the storage, use, and processing of data
gathered does not always take place in Germany. If the parties are based in Germany and the data are used do-
mestically, the provisions of the Federal Data Protection Act shall apply. If the provider of the app is located in
another EU Member State or within the European Economic Area (EEA), the so-called registered ofﬁce principle
according to Article 1 (5) clause 1 of the Federal Data Protection Act (BDSG) shall apply and the respective data
protection law applicable there shall apply. Only when the provider is based outside the European Union or the
EEA, once again Article 1 (5) clause 2 BDSG shall apply if data is collected in Germany via an app (Gola, Klug and
Körffer 2015, paragraph 29 cited according to Baumgartner 2013, paragraph 198). However, it is questionable
here to what extent German data protection law can also in fact be effectively enforced with respect to app
providers outside the EU in the latter case (Baumgartner 2013, paragraph 201).
For users located in Germany, full implementation and enforcement of German data protection requirements
guarantee appropriate data protection. In addition to the aforementioned problems in the context of inter-
national app offerings, in particular the abuse and the failure to implement the requirements can be problem-
atic.
It should be noted that comprehensive data protection legislation exists in Germany. In addition, harmon-
isation of regulation in Europe will also be implemented shortly in the form of the General Data Protection
Regulation. Particularly health data are legally privileged. If the legal provisions are in connection with the
use of apps, the existing level of protection can be transferred to the area of apps. Shortcomings are to be
due to the manner of implementation by the providers, the lack of transparency in obtaining informed consent
and providing adequate information, as well as the sensitivity of users in connection with privacy issues. The
protection of minors in relation to data utilisation is problematic, irrespective of whether they are adoles-
cents that have the necessary cognitive capacity and are able to give consent. In effect, when using apps,
it is possible for minors to grant consent to the collection, processing and utilization of data, without their
legal guardians having consented to this or the minors themselves being able to understand the scope of their
decision (Buchner 2006, paragraph 247; Baumgartner 2013, paragraph 326). This does not constitute valid
consent. It is questionable whether the data are still being processed and used.
A consistent implementation of the existing regulations and the creation of appropriate clarity and trans-
parency in information and consent would promote the exercising of the individual right to informational self-
determination. Whether ofﬁcial regulations for providing information and obtaining consent can contribute
³ The Constitution for the Federal Republic of Germany in the version published in the Federal Law Gazette Part III, outline
number 100-1, as most recently amended by article 1 of the law of 23 December 2014 (Federal Law Gazette I p. 2438).
4 BVerfG, judgment of 15 December 1983 – 1 BvR 209/83, 1 BvR 269/83, 1 BvR 362/83, 1 BvR 420/83, 1 BvR 440/83, 1 BvR
484/83, BVerfGE 65, 1-71.
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to appropriate transparency is open for discussion. Because apps are commonly distributed via app stores, a
joint commitment, and, if necessary, an obligation for the app stores to review apps should be discussed.
6.2 Health Apps as Medical Devices
Health apps can be classiﬁed as medical devices in the legal sense, depending on the intended use stated by See Chapter 11. Health Apps as
Medical Devices.
Oliver Pramann
the manufacturer. Whether an app is a medical device or not depends on whether it meets the deﬁnition of
Article 3 No. 1 MPG. This is always the case if the app is used for diagnostics or treatment. If the manufacturer
rules out a medical purpose for apps that include corresponding features, this must be clearly and unequivo-
cally identiﬁable (Gassner 2015, Possienke 2015, Pramann and Albrecht 2015, Heimhalt and Rehmann 2014a,
Heimhalt and Rehmann 2014b, Pramann and Albrecht 2014, Backmann 2011). However, whether there is a
distinct medical purpose is an individual decision, and this also has an impact on the exclusion of medical
purpose. There are already various guidelines available to manufacturers and users (BfArM 2015), including
those issued by the authorities, but these are not binding and may not apply to individual cases.
Till now, a number of questions regarding the regulatory requirements for health apps are still open. Apps that
are medical devices ﬁt into the existing framework of the medical devices law. Their safety can thus also be
veriﬁed based on the existing rules. In practice, however, making a distinction between apps that are subject
to the Medical Devices Act and those where this is not the case, proves quite difﬁcult (Pramann and Albrecht
2014, Pramann and Albrecht 2015). There is legal uncertainty here, in particular for manufacturers and users.
Although it is generally possible for the authorities to audit the manufacturers and to intervene if necessary,
depending on the circumstances, it is impossible to do so consistently.
With regard to the problem of delimitation, binding administrative regulations with delimitation criteria and
examples would make a contribution to the harmonisation of the rulings in this new ﬁeld. As it essentially
comes down to the purpose when making a distinction between apps that are covered by the Medical Devices
Act and those that are not, it could be considered to make it obligatory to prominently and visibly state the
purpose of health related apps. This obligation could be integrated into consumer protection laws, as these
would also apply to apps not covered by the Medical Devices Act.
Apps that are medical devices are, like other medical products, divided into risk classes according to potential
risk (Annex IX of Directive 93/42/EEC). They will often be assigned to class I if they have a correspondingly
low potential risk. It remains to be seen whether group of apps will evolve that exhibit a higher potential risk,
which could justify the general classiﬁcation in a higher risk category. For apps that can give laymen a self-
diagnosis and treatment, for example, it can be discussed to what extent they should generally be allocated to
a class higher than class I. This would result in the necessity to involve a notiﬁed body, which would provide a
further inspection instance for assuring safety, independent of the manufacturer and in compliance with the
necessary harmonised standards.
7 Health Apps in Statutory and Private Health Insurance
Health insurance funds and health insurance companies are crucial to the reimbursement of costs for the care See Chapter 12. Health Apps in
Statutory and Private Health Insur-
ance.
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of insured persons. As a (complementary) form of care, mHealth is relevant to the insurance providers.
An analysis of the market situation was conducted in terms of apps, the reimbursement possibilities as well as
the effects and incentives for statutory and private health insurance (systematic literature search, Internet
research, quantitative survey of insurance companies). The offer and the ﬁnancing of apps in the German
health insurance systemwere examinedmore closely. As there is only little evidence in relation to the different
questions that were examined, the analysis can only be seen as a ﬁrst step to tackling the topic of “apps and
health insurance funds/providers”. It is therefore necessary to perform further scientiﬁc studies to discuss
the use of apps from the perspective of the insurance providers.
Even now, some health insurance funds/providers already offer their own apps with different functionalities,
in particular with the aim of gaining/retaining customers and reducing administrative costs. The results of
the survey of health insurance companies showed that future apps should contain a number of functions that
– if sustainable use takes place – provide those insured with added value. For insurers, the importance of apps
will grow continually. For patients, using the apps on offer can contribute in particular to an optimisation
of self-management. This can lead to improvements regarding health-conscious behaviour, adherence and
compliance, thus resulting in reduction of costs for healthcare in the long term.
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7.1 Service Applications, Health Promotion and Prevention in the Foreground
From a competitive perspective, both service applications and apps for health promotion and prevention are
particularly valuable. For insured persons, service apps can represent a low threshold offer, which they can
use to obtain information about health topics in a simple manner. With the help of targeted offers for health
promotion and prevention through apps, health insurance funds/providers want to catch the attention of
young persons and win them as customers. The actual health beneﬁts of such prevention apps, however,
remain unclear and should be evaluated further.
7.2 Little Interest in Apps for Diagnostics and Treatment
To date, apps for diagnostic or therapeutic purposes are not of great interest to the health insurance com-
panies. There are, however, ﬁnancial incentives to offer or develop apps when implementing new forms of
healthcare and in the context of selective contracts. This can save costs and ensure the provision of care to
those insured. To make it possible for the insured to successfully use apps in the context of diagnostics and
therapy, professional advice and guidance are needed. In this regard, apps are no different from other medical
services. Especially in the area of diagnostics and treatment, a high quality of apps in terms of operability,
comprehensibility and privacy is of particular relevance. For each individual app, its medical beneﬁts must
be evaluated. Therefore, the few existing apps are offered through special forms of healthcare or selective
contracts of individual health insurance providers. To make use in standard care possible and to achieve an
improvement in healthcare in this way, the question of reimbursement by the payers must be solved (Kaufmann
2014, Zuck, 2014, Rübsamen 2015). To that end, clear criteria and requirements should be formulated for pos-
sible reimbursement of the costs, and these speciﬁcally need to take possible damages and risks resulting from
the use of apps into account. It is also questionable to what extent the efﬁcacy of apps can be evaluated in
currently typical clinical trials or whether special requirements must be formulated for apps. For manufac-
turers and providers of apps to be used for diagnostics or therapy, it is important that there is transparency
and security as regards reimbursement of the costs in standard care. Equally, for apps outside the context of
diagnostics and therapy, the reimbursement process should also be uncomplicated and easily accessible, in
order to make sure that the apps are put to use. It is essential to determine whether and, where appropriate,
how the reimbursement processes for an implementation of apps in standard care need to be adapted. It must
still be observed whether conventional services will be strongly substituted with apps, which could lead to a
discrimination of certain population groups such as the elderly and non tech-savvy persons. In addition to
the questions of the reimbursement of costs, the quality of apps offered is also paramount. Currently, the
quality of apps is very heterogeneous. Therefore, it is important to develop generally valid quality criteria that
facilitate safe use.
7.3 Data Acquisition and Processing with Apps – a Domain of Private Health
Insurance
With regard to the use and the offer, there is primarily a difference between the statutory healthcare and
private healthcare when it comes to data acquisition. For statutory health insurance, the possibilities of the
use of data are legally very severely restricted and pose a problem with respect to a breach of privacy by insured
persons. Statutory health insurance has so far mainly used apps in bonus programmes. To that end, however, it
must be demonstrated that savings are actually facilitated and efﬁciency increased through the use of an app.
So far, there is little evidence in this regard, which must be seen critically. In addition, the ﬁnancial impact of
such bonus programs should be limited so that there is not a general increase in premiums. These additional
offerings must also continue to support themselves. Private health insurance can theoretically use the data
collected with the help of apps for the calculation of premiums adequate to the risk. Currently, this is not yet
the case. Health-conscious behaviour is only rewarded in the context of incentives (e.g. Generali 2015), much
like in statutory health insurance. However, the development of regulatory requirements is necessary. An
indirect pressure to use appropriate apps could follow if a non-use has a negative impact on the calculation of
premiums. To date, limited access to health-promoting or preventative apps (e.g. because of age or illness) still
has no direct negative effects because the ﬁnancial consequences of non-use of bonus programs or incentives
are low.
In statutory health insurance, there are already strict privacy rules with regard to the collection and retention
of social data (Article 284 (1) SGB V). However, the data protection obligations and their compliance by third
parties, such as intermediaries or app providers, are not entirely clear. In private health insurance, the data
protection requirements are based primarily on the Federal Data Protection Act. Now it is a case of improving
transparency with regard to data collection, use and storage, and establishing clear regulations.
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8 Guidance
8.1 Orientation for Users of Health Apps
Among the variety of products, users of health apps are facing the challenge of identifying a suitable and See Chapter 13. Orientation for
Users of Health Apps.
Urs-Vito Albrecht
trustworthy one.
8.1.1 Identifying a Trustworthy App
Users should consider different aspects in order to identify trustworthy and high-quality offers. Already before
installing an app, they have to identify who is responsible for the app andwhat functions it contains. The limits
of the application should also be made clear here. An app should only be used if it is recognisably up-to-date.
The quality of the information provided in the app can be estimated, amongst other things, on the basis of the
qualiﬁcation of the manufacturers. Only if it is shown that an app has been implemented by qualiﬁed persons
according to the state of technology and medicine, should it be trusted. Users also need to be sure the app
has been designed for the intended purpose of their application and for them as a target group (Albrecht, Noll
and von Jan 2015, Yasini and Marchand 2015, Voas 2003, Ben et al. 2010).
As regards health apps, the presence of a full privacy policy is particularly important. The privacy policy
should inform the user in plain language about the data processing behaviour of the app. Users should also
critically question the permissions requested by an app. Once an app demands more access than is necessary,
it should not be used. Apps that have a clear medical purpose based on their functions and the description by
the manufacturer and are thus to be regarded as a medical device, but are not marked as such, should not be
used.
Quality labels can also speak for the quality of an app if the underlying testing method is validated. The same
applies to studies that have been conducted according to scientiﬁc standards. Often, apps are evaluated by
other users, and the results of the reviews are presented in the app store. These reviews can serve as a ﬁrst
assessment of the quality, but should not signiﬁcantly affect one’s personal assessment.
8.1.2 Current Guidance and Evaluation Platforms
The existing guidance and platforms for users are very heterogeneous in their objectives, business models and
concepts (see, for example, afgis 2012, Albrecht, Pramann and von Jan 2015, imedicalapps.com, app-check the
“Centre for telematics and telemedicine GmbH” (ZTG), “HealthOn-app honour code” (HealthOn)). To date, none
of the various methodological approaches (codes, seals of quality, reviews by professionals or lay users) have
prevailed for the detection of quality and trustworthiness. The transparency of providers in relation to quality
criteria and veriﬁcation processes and the internationality of the appmarket represent further problems. There
is still no comprehensive and at the same time valid guidance for assessing the trustworthiness of health
apps.
8.1.3 Developing Appropriate Tools
The development of decision aids for users is very important due to the prevalence and increasing use of health
apps. All players (manufacturers, users, initiatives, certiﬁers, etc.) must be integrated to achieve a maximum
credibility and acceptance. Several steps are necessary for the development of guidance. The exchange be-
tween players (communication) and the agreement on quality and trust aspects (consensus about elements of
trusted software) are the top priority. Then, strategies must be developed for the production of high-quality
and trustworthy products and their safeguarding or approval procedures/review. In addition, transparency in
relation to the products and their manufacturers must be promoted. Finally, targeted information must be
made available to all participants (information/education) and incentives must be created for the implemen-
tation of quality-assured and trusted applications (promotion). The industry has a particular responsibility at
this point. The aim is to promote certiﬁcation initiatives that offer valid and transparent test procedures in
order to provide users with trusted guidance.
This process should be conducted by a superior, economically independent state initiative. Continuous up-
dating and adjustment of the measures is necessary because the app market develops very fast. Therefore, a
comprehensive and up-to-date review of all health apps by an ofﬁcial body is not realistic. Rather, multiple
approaches should be pursued to meet the different needs arising from different usage types and locations.
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8.2 Guidance for Professional Users of Health Apps
Health apps are used in the treatment context. It is expected that patients will increase demands on theirSee Chapter 14. Orientation for
Professional Users of Health Apps.
Tobias Hartz, Ute von
Jan & Urs-Vito Albrecht
suppliers (Behrends et al. 2015). Healthcare providers will also want to make fuller use of apps. In other
countries, mobile devices are already widely spread across all layers of the population and there is a high
utilisation rate of apps in the health context both on the part of doctors and patients. Here, healthcare
providers are already increasingly giving app recommendations to their patients (Zhang and Koch 2015).
8.2.1 Offers for Professional Users
The trend towards using apps in the healthcare sector is also increasingly detected by software providers. There
are tools and applications for patients that not only allow them to research information on health issues and to
capture andmanage data in the health context, but also send these to their doctors in a manner compliant with
data protection regulations. Apps with a speciﬁc focus on medical professionals are also being increasingly
used. In addition to health apps, where special requirements in the area of health have already been considered
during their development process, there are also apps that were originally focused on a different application
area (Johnston et al. 2015, Drake et al 2016, Giordano et al. 2015). Nevertheless, these apps can also perform
in the health sector if used appropriately.
8.2.2 Guidance is Necessary, But Rarely Available
Policy recommendations for health professionals that consider handling of apps or provide help on how to
recommend apps to patients are virtually non-existent.
Therefore, mandatory criteria, e.g. in the form of ofﬁcial guidelines, are needed, which providers can use
to ensure the legally safe and ethically acceptable use of health apps. These have to answer a number of
questions.
Both with regard to their own use and in relation to possible app recommendations, it is important that health-
care providers recognise that not every app is appropriate for the medical context. This is also in their own
interest: if healthcare providers use an app that is not explicitly intended for the particular purpose, in case of
doubt they can be made liable for any damage, over which they have no inﬂuence (e.g. malfunctioning of the
app). However, professional users are rarely able to carry out a comprehensive assessment of the suitability of
apps in general or those for speciﬁc application areas. In addition to possible uncertainties from a technical
perspective and in terms of content, sensitive data are handled in a far less critical manner, as a rule. Potential
damage and risks that may arise thereby seem rather theoretical and not immediately ascertainable for many
users. The direct and immediate consequences are rarely visible to them. Especially for apps that are used
for communication or data exchange, there still appears to be insufﬁcient awareness of the problem. Partly
enthusiastic reports about the use of messenger apps and services for communication about patients can also
be found in the literature (Johnston et al. 2015, Drake et al 2016), but usually without going into further detail
on data protection concerns.
8.2.3 Identifying Quality, Utilising Opportunities and Minimising Risks and Dangers
Based on their own skills, healthcare professionals can only judge the quality, suitability, and trustworthiness
of an app to a limited extent. However, healthcare providersmust ensure when using apps in a professional con-
text that the apps are suitable for the respective area of application (healthcare, research and education and
training). In addition to the technical assessment of the medical content, which can be performed through-
out, the assessment of technical, legal and ethical aspects, which are also relevant, is normally more difﬁcult
without further assistance. For meaningful and legally compliant use of apps in a professional context, an
intensive consideration of the opportunities and risks of apps in healthcare and the provision of appropriate
recommendations, guidelines and structures for the healthcare providers is required. For example, they should
only use apps with a medical purpose if they carry a CE mark (Royal College of Physicians 2015).
Appropriate recommendations on the use and an assessment of the respective app also only work if health-
care providers can rely on the information available on the respective app, which, in addition to information
from the manufacturers, may include certiﬁcates, labels, etc. The heterogeneity of the current situation was
outlined in the previous section. The aforementioned creation and promotion of certiﬁcation initiatives with
valid and transparent review processes may prove helpful.
When using apps, compliance with the applicable laws represents another essential aspect for healthcare
providers. In this context, it must be ensured that the regulations on remote treatment, according to which
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no exclusive treatment via communication media may be carried out (Bundesärztekammer 2015), are complied
with, and it must also be ensured that a doctor treats the patient in person. An app can therefore only ever
represent a complement to the treatment and healthcare concept; otherwise, liability issues may arise. Difﬁ-
culties may also be experienced with regard to long-term monitoring of patients, since it cannot be assured
that a doctor who knows the person concerned personally constantly evaluates the data and can intervene in
case of doubt.
Even though apps with their original purpose lying outside of the medical area (for example messenger apps)
are often used to exchange information with colleagues about common patients, this can prove problematic.
The aspects of data protection are the top priority here. In this regard, for many providers of communication
apps, the requirements of the health area do not ﬁt with the regulations contained in the terms and conditions.
In addition, a corresponding use often takes place on private devices. A clear separation between professional
and private use is desirable, but often difﬁcult to enforce in practice when using mobile devices. Also, the
data security and data integrity of apps can be endangered by using other apps on the same device. There is a
threat of legal consequences if patient data inadvertently falls into the wrong hands. This problem should be
drawn to the attention of both doctors and other healthcare professionals.
8.2.4 Measures That Can Offer Guidance
Overall, the promotion of awareness-raising campaigns seemsmeaningful in addition to the design of guidance.
Policy makers should support this idea and push for more ﬁrmly integrating information about the adequate
use of apps into the education and training of healthcare providers. The improper use of apps should be more
strictly regulated. At the same time, alternatives must be created and relevant projects must be promoted. In
general, tools such as guidelines, recommendations and certiﬁcates, which serve a better evaluation of apps,
must be promoted or provided by decision makers.
8.3 Guidance for Manufacturers of Health Apps
A cornerstone for a safe and successful use of health apps is that all quality-relevant aspects have already See Chapter 15. Orientation for
Manufacturers of Health Apps.
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been considered adequately during their planning and development. However, some developers overlook the
potential health risks of their apps as well as relevant regulatory aspects for health apps in particular. The de-
velopment of health apps of suitable quality must be guaranteed by the manufacturers irrespective of whether
the app is a medical device or not. Manufacturers, from large companies to small start-ups and amateur devel-
opers, do not necessarily have the required knowledge. Guidance as issued by the Federal Institute for Drugs
and Medical Devices (BfArM 2015), the American FDA (2015) or the German Association for the Electrical En-
gineering and Electronics Industry (ZVEI 2014) and the Düsseldorfer Kreis (2014) can give a ﬁrst reference for
health apps.
8.3.1 Various Quality Standards
Though the question of criteria for a high-quality app is relevant, it is also difﬁcult to answer. The concept
of quality in itself leaves much room for discussion. In the industry, quality is understood as the degree of
compliance with clearly deﬁned requirements. The requirements may vary depending on the industry sector.
In general, quality is an obvious part of each product. The concept of quality and quality management pro-
cesses form the starting point for production in a variety of industry sectors. In the ﬁeld of health apps, this
obviousness is not present to date.
8.3.1.1 The Fundamentals of Quality-Assured Development
Beyond the usual standards of software development, as set out for example in the ISO 250xx series of stan-
dards, there is currently little clarity about which quality criteria should be taken into account in the ﬁrst
place. The fundamental quality criteria in the ISO 250xx of series of standards include, for example, consid-
ering the intended functions (functionalities) and those relevant to the user, a suitable ratio of performance
and cost (efﬁciency) and also the possibility of cooperation, exchange and/or coexistence with other products
(compatibility). Moreover, the operation should be easy and special needs (for example accessibility) should
be considered. Similarly, reliability and the implementation of adequate data protection and data security
measures are required. In addition, maintenance and care should be implemented in such a way that the ser-
vices of the software are available continuously (maintainability). Furthermore, it should be possible to adapt
to different conditions of use (portability). ISO 9001 deﬁnes quality standards in particular with regard to the
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quality management of products and services. Nevertheless, the deﬁnitions and standards of quality described
here are rarely considered in the implementation of apps if the market is to be looked upon in its entirety.
8.3.1.2 Additional Requirements in the Context of Health
A number of additional requirements should be considered in the health sector. The priorities are user security
in relation to the physical integrity and/or health of users, but also the integrity of the data collected and
processed. If risks cannot be ruled out, safety mechanisms are to be implemented, for example, by informing
users of a possible problem using alarm or notiﬁcation functions. Also, transparent information of all players
about the risks is to be ensured, especially regarding those which cannot be turned off or for which no adequate
safety measures are (or can be) taken. Compliance with existing legal requirements, which in the area of health
go far beyond those in software in general, must be guaranteed. For apps that are represented as medical
devices, there are requirements in the form of IEC 62304 and other standards that need to be considered as
regulatory minimum. It is unclear, however, whether the requirements described herein are sufﬁcient. In
addition, there is a potential for conﬂict between the understanding of quality presented here and that in ISO
9001. Whereas ISO 9001 speciﬁcally looks at the satisfaction of explicitly expressed and implicit requirements
or needs of relevant stakeholders (customer satisfaction), the safety of patients is in the foreground in ISO
13485.
8.3.2 Development of Health Apps on the Life Cycle
The planning must consider the relevant processes for project management and deﬁne to which processes the
software development itself is subject. Differentmodels are available. These differ essentially in their methods
that range from linear processes through interactive iterative structures to agile models. In addition to the
implementation, the planning is also subject to an iterative and incremental approach, in which problems can
be responded to rapidly.
In the design phase, the considerations and ﬁndings of the planning are transferred to software architecture
and software design, which should serve as a blueprint for the subsequent implementation. In this step, it is
deﬁned how ﬂexible the future product will be and how it can be integrated into the IT landscape in the context
of other information systems. The speciﬁcation of the data model, the product features and the interfaces are
important aspects in the design phase.
The implementation phase serves as a gradual transformation of the planning towards a functional app. New
insights inevitably arise here that were not or could not be adequately addressed in the planning phase because
the context framework conditions at the time of the planningmay have changed prior to the development (e.g.,
operating system updates, new frameworks or equipment, etc.).
As stated in the planning and requirement analysis, the app is subjected to various tests. These take place
on various levels and with various means. These could include a (automated) testing of the source code of
the app or product features based on deﬁned test cases as usability tests. The results of the tests are to be
documented.
Once the road has been paved from the requirements through the design and implementation to the veriﬁcation
and validation of a software system, the provision of the software for external users follows. If the health app
is a medical device, this is to be equated with the placement of the product on the market. Corresponding apps
may only be published if there is a valid CE marking. The “essential requirements” according to 93/42/EECmust
be met for this purpose, namely a conformity assessment procedure has been completed and a declaration of
conformity has been issued prior to the publication. In addition, ﬁrst-time placement on the market is to be
reported to the German Institute of Medical Documentation and Information (DIMDI).
On the other hand, the maintenance aims to ensure the continuous operation of the app. On the other hand,
it is about extending the functionality and reducing sources of error and barriers. The existing quality should
at least be retained. As a rule, an improvement is achieved. Any irregularities discovered must be documented
and communicated, as well as the measures taken to remedy the situation. For a medical device, it is in par-
ticular important to identify the possible risks of a medical device placed on the market (for example, based
on customers’ feedback) and to respond to this. Even if the Medical Devices Act does not provide a speciﬁc
deﬁnition of the term “risk”, adverse effects, reciprocal inﬂuences, malfunctions, technical defects, contra-
indications, falsiﬁcations or other risks associated with medical devices, which are named in Article 31 of the
Act in the regulations for medical device consultants, are to be documented. A respective legal procedure in
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form of relevant reporting obligations of safety aspects is provided in the Order on the Recording and Assess-
ment of, and Counteractive Measures for, Risks Linked to Medical Devices (Safety Plan for Medical Devices –
MPSV).
8.3.3 The Intended Purpose Leads the Way
The intended purpose has a key role in all considerations. It can be considered the foundation of an app and
is to be chosen carefully right at the start. An app receiving a relevant purpose only in the course of time can
result in large costs. The purpose must be kept in view in all activities and also be communicated clearly and
unambiguously to the users.
As the rapid development cycles and the sheer number of available apps hardly allow for a comprehensive
quality control by third parties, manufacturers should disclose the quality criteria they use as far as possible
so that users can inform themselves better and more easily.
The health app is only taken seriously as a tool in the context of health if it meets the quality requirements in
relation to safety, usability, functionality and transparency. The quality-assured development is an essential
component to offer applications that can be used with conﬁdence in the health context. In the long-term,
only the apps that also earn this trust will take precedence. If this subject is not consistently and adequately
addressed, the sustainability of this technology is unlikely, as it will not be accepted by all of the players.
9 Fields of Action, Possible Actions and Players
To improve the overview and to provide a basis for future discussions, ﬁelds of action with action options and
the players, which are or need to be primarily involved (from the author’s point of view), are presented in a
summarised form5. 64 speciﬁc options for action can be derived from the chapters (see table 2). These are
assigned to nine ﬁelds of action: (a) organisation and infrastructure, (b) ﬁnancing, (c) access, (d) ethics, (e)
regulation, (f) research, (g) quality, (h) transparency and (i) information. The players are divided into nine
groups: Federal Government / Federal States, stakeholders, manufacturers, providers, lay users, professional
users, researchers, healthcare institutions and payers (see table 1).
For many of the listed options of action, several players need to be involved. To emphasise which player is seen
primarily as the initiator of the respective course of action (from the perspective of the project team), in the
table, the initiators () are differentiated from other relevant players. () If the costs of an action option can
be attributed to one or more players, who are not simultaneously seen as the initiator of the option concerned,
they are speciﬁcally marked (e). Depending on the chosen manner of implementing an action option that is
not exhaustively described in this document these assignments may be subject to change.
Table 1: Overview of the players.
Player Explanation with examples (not exhaustive)
Federal Government / Federal
States
Political institutions on Federal and State levels (including the Federal Ministry of Health
(BMG), state ministries of health, the Federal Institute for Drugs and Medical Devices (BfArM),
the Federal Ofﬁce for Information Security (BSI), the Federal Commissioner for Data Protection
and Freedom of Information (BfDI), the Federal Centre for Health Education (BZgA), the Federal
Government Commissioner for Patient’s Affairs and Representative for Care).
Stakeholders Stakeholders, associations, public law bodies (including the Aktionsforum Gesundheitsinfor-
mationssystem (afgis) e.V., the German Medical Association (BÄK), ZTG Zentrum für Telematik
und Telemedizin GmbH, the German Dental Association (BZÄK), the German Disability Council
(DBR), the German Federation for the Deaf(DGB), the German Hospital Federation (DKG), the
National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), the National
Association of Statutory Health Insurance Physicians (KBV), the National Contact and Infor-
mation Point For Encouraging and Supporting Self-Help Groups (NAKOS), the Private Health
Insurance Association (PKV), the Federation of German Consumer Organisations (VZBV)).
Continued on the next page
5 Our thanks to Tobias Hartz and Mrs Uta Hillebrand for assisting in the revision.
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Player Explanation with examples (not exhaustive)
Manufacturers Persons and bodies responsible for developing the app (e.g. software companies, programmers).
Providers This player can overlap with others. However, the actual provider through which a person can
obtain an app (including app stores) is primarily meant in this context.
Lay users Users who do not use an app in the professional context (primarily the health-conscious and
patients).
Professional users Healthcare providers who use the respective app in a professional context.
Researchers Persons and institutions that look at the apps in a scientiﬁc context (including universities,
colleges and other research institutions).
Healthcare institutions Institutions that are involved in the direct care of patients (including hospitals, medical service
centres, practices).
Payers Parties carrying the costs for healthcare in its original sense (such as health insurance funds,
health insurance providers, pension insurance).
Table 2: Overview of ﬁelds of action, options for action, and players.
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(a) Organisation and infrastructure
Situation: Organisational structures and existing infrastructure in the health sector are not adequately prepared for the additional
requirements arising from the comprehensive use of mobile health applications (mHealth). Solutions are often only sought and imple-
mented for issues limited to regional demands or speciﬁc topics.
01. Transformation of the German healthcare system towards a learning organisa-
tional structure.
    
02. Making organisational structures and processes transparent and guaranteeing
better protection against vested interests.
    
03. Development of an adaptable eHealth/mHealth strategy with a focus on function-
ality and results rather than on speciﬁc (isolated) solutions.
    
04. Establishing eHealth and mHealth-based approaches more strongly and perma-
nently in healthcare processes (e.g. via infrastructure measures, ﬁnancial incen-
tives).
   e
05. Expanding the necessary technical infrastructure to promote and ensure exten-
sive care with (mobile and stationary) broadband Internet access.
   
06. Clarifying deﬁnitions and – where necessary – establishing new standards or
adapting existing standards (interoperability).
e        
07. Boosting internationalisation through development of internationally compatible
standards.
    
08. Identifying what is actually needed for providing care.         
09. Promoting the development of offers tailored to speciﬁc needs / requirements.    
10. Promoting health apps that have easily visible beneﬁts and are user-friendly (mar-
ket openers).
  
11. Breaking down barriers for disadvantaged groups (e.g. through the availability of
cheap basic tariffs, educational measures, technical equipment).
      
(b) Financing
Situation: So far, in part due to unresolved ﬁnancing, mHealth solutions and speciﬁcally adapted apps have not found their way into
established care processes of the primary health market. Being a prerequisite for this, scientiﬁc evidence of the efﬁcacy is not yet
consistently available.
Continued on the next page
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12. Displaying ways of reimbursement of costs of apps / transfer to standard care.     
13. Formulating criteria and requirements for the reimbursement of costs, while tak-
ing into account possible risks.
    
14. Clarifying remuneration of service providers in the context of (telemedical)
healthcare.
      e
15. Creating ﬁnancial incentives to improve cross-sectional care (hospital, rehab fa-
cilities, treatment at home, etc.) with the help of mHealth-based solutions.
   e
(c) Access
Situation: Due to a number of reasons, equal access across all population and user groups has so far not been guaranteed. Financial
reasons (cost of purchasing devices and apps, expensive mobile tariffs), as well failure to respect special requirements (physically or
cognitively handicapped groups, elder generations) are relevant here in addition to technical reasons (e.g. lack of infrastructure).
16. Promoting digital literacy and health competencies across all the population
groups by expanding educational offers (from nurserys / schools to basic and ad-
vanced education and training and adult education) in all areas of life.

17. Promoting the development of offerings oriented around needs / requirements
(apps, healthcare concepts, …) to improve healthcare for otherwise difﬁcult to
reach groups that could disproportionately beneﬁt from the implementation (ru-
ral population, rare diseases, …)
   
18. Promoting barrier free offers.     
(d) Ethics
Situation: Innovative technologies generate interest in many places. An ethical assessment of the potentials as well as hazards of the
technology for the individual (loss of control of their own data, privacy, transparency etc.) and the community is necessary.
19. Discussion of equal access to care through mHealth.         
20. Discussion of protection of privacy and transparency.         
21. Discussion of autonomy and control.         
22. Ethical guidelines for developing, recommending and using health apps.         
(e) Regulation
Situation: Existing regulations for medical devices, data protection, etc., do not adequately respect the speciﬁc needs arising from
the international character of the market for health apps. Due to the vast number of apps, a comprehensive review of health-related
apps by the authorities is impossible. Measures which generally assist with gaining a better understanding of apps being offered or
improve the availability of information needed for assessing health apps may be of help.
23. Developing a low-threshold vigilance system for keeping track of incidents or un-
expected events (data protection, health risks, etc.) that can occur when using
health-related apps.
        
24. Strategically focusing on cross-application regulations. 
25. Promoting the development of guidelines, policies, certiﬁcates, recommenda-
tions and structures to create transparency.
   
26. Implementing legally compliant criteria for the development, use and design of
health apps.
 
27. Obliging the stores to critically assess fundamental aspects of quality for health
related apps they offer.

28. Creating a legal obligation to clearly state the purpose of apps related to health. 
29. Create binding administrative provisions that contain demarcation criteria and
examples (e.g. with respect to distinguishing between apps that are medical de-
vices and those that are not, risk classes) as a contribution to the harmonisation
of rulings.

Continued on the next page
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30. Develop and label data protection standards.  
31. Agreeing on the requirements / precise content of comprehensive information
that must be provided with respect to data protection.
        
32. Introducing or expanding an information obligation for manufacturers. 
33. Develop and implement appropriate (organisational) measures to reduce the risks
arising from the use of health apps.
       
(f) Research
Situation: Like all other measures in the healthcare, health apps as well as app-based care and prevention concepts need to prove their
effectiveness in scientiﬁc studies if they are to take permanent hold in healthcare. Currently, there is only limited comparability of
studies that evaluate apps or make use of apps for research purposes. Often, due to the rapid development cycles of apps, there are
only small studies of short duration with a rather narrow focus.
34. Promoting scientiﬁc evaluation of app-based concepts across various sectors.   
35. Where appropriate, app-based concepts need to be evaluated across sector bound-
aries.
  
36. Promoting long-term (accompanying) evaluations of app-based concepts.  
37. Implementing long-term evaluations of app-based concepts.    
38. Standardising studies with apps (to facilitate comparability).     
39. Scientiﬁcally evaluating the beneﬁts of apps for various health-related areas of
application.
      
(g) Quality
Situation: In the context of health, only high-quality apps should be used to ensure safety and functionality. But consensus is currently
lacking as to what lies behind the concept of quality. Coordination is necessary to be able to subsequently develop standards and assess
“quality”. On the one hand, appropriate steps need to be taken to promote the exchange between the different players to prevent that
the needs of the users are not duly respected during development. On the other hand, care must be taken to ensure that fundamental
quality aspects are known and are taken into account from the point of conception and over the period of development to the actual
use.
40. Creating mandatory quality speciﬁcations for development.   
41. Establishing quality standards beyond the scope of the Medical Devices Act.     
42. Develop participation formats for the various stakeholders.  
43. Provide incentives and support for developing, using, providing and recommend-
ing trusted products.
 
44. Promote initiatives for assessing the quality of apps.    
45. Develop general quality criteria for apps that may serve as guidance for manufac-
turers as well as users.
        
46. Use quality-backed development processes, including risk analysis prior to imple-
mentation, in order to be able to reduce potential hazards.
 
47. Develop methods appropriate for evaluating the beneﬁts of apps (e.g. for proving
their efﬁcacy for possible reimbursement of costs) in the context of healthcare
research.
  
48. Create a platform to facilitate exchange between developers and users (user
groups) for better focused product development.
e   
49. Involve the target group in the process of developing apps to make allowances for
speciﬁc needs.

50. Develop strategies for developing trustworthy offers.         
51. Develop guidelines for manufacturers.   
52. Promote the development of barrier-free services.  
Continued on the next page
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(h) Transparency
Situation: Adequate information that can support users and neutral third parties in assessing apps (content, functionality) is not
provided by all manufacturers in a transparent manner. However, such information is necessary in order to be able to assess and
evaluate applications and measures. If it is missing, both implementation and use are subject to uncertainty. A lack of trust in the
technology may slow down or even impede its use despite its potential.
53. Disclose the quality criteria used.   
54. Promote transparency of products / manufacturers.    
55. Request additional information relating to the medical content and intended pur-
pose(s) of the application from developers, as well as data protection with special
reference to the requirements in a health context (similar to the age classiﬁca-
tion); transparent reporting about existing risks.
 
56. Encourage manufacturers to compile information about the entire manufactur-
ing process from the very start of the development process, with data covering
privacy aspects and the results of the risk analysis conducted prior to develop-
ment. The information should be made available in a suitable location (stores)
upon publication.
 
(i) Information
Situation: Users are not aware of all criteria necessary for assessing health apps. Both in private and professional context, health apps
are often used unreﬂectingly. There are uncertainties about usage. This can result in risks both in terms of health and in terms of
jeopardising sensitive personal or health-related information. This may also result in poor utilisation and a failure to exploit the full
potential of the technology. Available sources of information about health apps are confusing, and of variable quality. Neutral and
quality-assured services need to be developed to ﬁll this gap. Guidance that lists and explains these services can be of help.
57. Develop tools such as guidelines, directives, certiﬁcates, recommendations and
promote structures that enable care providers to select, use and recommend ap-
propriate apps.
  
58. Design guidance for lay persons (healthy persons, diseased persons).    
59. Educate manufacturers about regulatory requirements and prerequisites for ap-
proval.
   
60. Design guidance for professional users.   
61. Design guidance for researchers.   
62. Facilitating orientation for users with respect to apps that are being offered (e.g.
via clustering in stores if standards and process are valid).
  
63. Comprehensive information on data collected and its use.       
64. Provide comprehensive information to all (potential) stakeholders (including pa-
tients and possible professional users) about risks / hazards and (organisational)
measures that contribute to their reduction or elimination.
       
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